The Employee Profile in China Pharma R&D

15 July, 2015

The Employee Profile in China Pharma R&D
Pharmaceutical companies are currently targeting the emerging markets of China and Africa for their future expansion, with the highest investment - USD 5.32 billion - just in China alone. Around 29 plants with a combination of manufacturing, production units and research & development centers are scheduled to open through the 2015 to 2022 period across regions. In addition to new facilities, approximately five brownfield expansions and nine closures are also scheduled within the same period. Figure 1 shows the various expansions vs. closures regionally planned by the top 10 big pharma companies

COVID-19: Assess impact on your suppliers and ensure business continuity with Beroe’s WIRE
(World Instant Risk Exposure)